1. Christian Schindler , Inga Strehlow . Cytokines and STAT Signaling . Advances in Pharmacology . 1999 ; 47 : 113-174.
2. Therapeutic potential of JAK2 inhibitors . Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636-642.
3. Yiming Luo MD , Madison Alexander BA , Massimo Gadina PhD , et al . JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition . Journal of Allergy and Clinical Immunology . 2021 ; 4(148) : 911-925 .
4. Ann Mullally , John Hood , Claire Harrison , Ruben Mesa . Fedratinib in myelofibrosis . Blood Advances . 2020 ; 8(4) : 1792-1800 .
5. FDA grants priority review to filing for Celgene's JAK2 inhibitor fedratinib in myelofibrosis , March 06, 2019.
6. GSK completes acquisition of Sierra Oncology , 1 July 2022, London UK .
7. Health Canada Approves INREBIC® (fedratinib) , First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis , Oncology , 21/09/20 .
8. Fuping Wang , Tian Qiu , Haitao Wang , Qiong Yang . State-of-the-Art Review on Myelofibrosis Therapies . Clinical Lymphoma Myeloma and Leukemia . 2022 ; 5(22) : 350-362.
9. US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis , 17 August 2022 .